IGC Pharma Inc risk profile
39 Normal where most of the sector sits
Measured 1 September 2026 from IGC's filed statements. Recomputed nightly.
39 (Normal), driven by Cash conversion at 100, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 68 | Stretched | Volatile | One-year price volatility — 54.2% |
| Operating pressure | 0 | Contained | Stable | Costs outgrowing revenue — -16.3 percentage points |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.02x |
| Leverage and coverage | 19 | Contained | Worsening | Current ratio — 1.28x |
| Competitive position | 45 | Elevated | Stable | Operating-margin gap against peers — -490.6 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.